Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing

鈥� An ASCO Reading Room selection

May 22, 2024

Megan L. Hutchcraft, MD, Shulin Zhang, MD, PhD, Nan Lin, MPH, MS, Justine C. Pickarski, MS, LGC, Elizabeth A. Belcher, MS, Sainan Wei, MD, PhD, Th猫r茅se Bocklage, MD, Rachel W. Miller, MD, John L. Villano, MD, PhD, Michael J. Cavnar, MD, Joseph Kim, MD, Susanne M. Arnold, MD, Frederick R. Ueland, MD, and Jill M. Kolesar, PharmD, MS.

JCO Precision Oncology

This Reading Room is a collaboration between 番茄社区庐 and:

Below is the abstract of the article.

Read the full article PDF by clicking here

or on the link below.

Purpose

Patients with cancer frequently undergo research-grade germline sequencing but clinically actionable results are not routinely disclosed. The objective of this study is to evaluate the feasibility of reporting clinically relevant secondary findings (SF) identified in germline research sequencing using the institutional molecular tumor board (MTB) and the treating oncology physician.

Methods

This prospective, interventional cohort study enrolled Total Cancer Care participants with any cancer diagnosis at a single institution. Patients underwent research-grade germline whole-exome sequencing, with bioinformatic analysis in a Clinical Laboratory Improvement Amendments–certified laboratory to verify pathogenic/likely pathogenic germline variants (PGVs) in any American College of Medical Genomics and Genetics SF v2.0 genes. After a protocol modification in consenting patients, the MTB reported PGVs to treating oncology physicians with recommendations for referral to a licensed genetic counselor and clinical confirmatory testing.

Results

Of the 781 enrolled participants, 32 (4.1%) harbored cancer predisposition PGVs, 24 (3.1%) were heterozygous carriers of an autosomal recessive cancer predisposition syndrome, and 14 (1.8%) had other hereditary disease PGVs. Guideline-directed testing would have missed 37.5% (12/32) of the inherited cancer predisposition PGVs, which included BRCA1, BRCA2, MSH6, SDHAF2, SDHB, and TP53 variants. Three hundred fifteen participants consented to reporting results; results for all living patients were reported to the clinical team with half referred to a licensed genetic counselor. There was concordance between all research variants identified in patients (n = 9) who underwent clinical confirmatory sequencing.

Conclusion

MTB reporting of research-grade germline sequencing to the clinical oncology team is feasible. Over a third of PGVs identified using a universal testing strategy would have been missed by a guideline-based approach, suggesting a role for expanding germline testing.

Read an interview about the study here.

Read the full article

Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing

Primary Source

JCO Precision Oncology

Source Reference:

番茄社区